Frexadigital AI Substudy: AI-Based Smartphone Video Assessments of Motor Function In RMS and Non-Relapsing SPMS Population (CMSC 2026) - Jun 2, 2026 - Abstract #NIB04; Pres time: May 28, 2026; 05:00 PM - 07:00 PM; Location: Exhibit Hall B (Charlotte Convention Center); P3 | " FREXADIGITAL AI is an optional exploratory substudy of the phase 3 FREXALT (RMS) and FREVIVA (nrSPMS) studies comparing the efficacy and safety of frexalimab to teriflunomide (FREXALT, NCT06141473) and/or placebo (FREVIVA, NCT06141486) over 24 months. This innovative approach offers a non-invasive, patient-centric, objective, standardized, and accessible method to estimate disease progression and treatment efficacy in people with MS."
Clinical • Video • CNS Disorders • Multiple Sclerosis
|
|
Pinar Kanlikilicer, PhD 1; Julia Chernova, PhD 1,2; Levi Walrath, BA 1; Albert Pla Planas, PhD 3; Amrut Sarangi, MEng 1; Mena Kamel, BEng, MESc 4; Hillol Sarker, PhD 1; Karim Benlahcen, PhD 5; Philippe Truffinet, MD 5; Luis Orozco, MD, PhD 1; Erik Wallstroem, MD, PhD 1; Elena Gargaun, MD, PhD 5
|